Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

10/06/2021 | 08:00am EST

Viracta Therapeutics, Inc. announced the initiation of a multinational Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors. The trial is designed to evaluate the safety and preliminary efficacy of nanatinostat in combination with valganciclovir (Nana-val) alone and in combination with the PD-1 checkpoint inhibitor pembrolizumab. The Phase 1b/2 trial is an open-label, multicenter trial evaluating Nana-val alone and in combination with pembrolizumab. The Phase 1b dose escalation portion is designed to evaluate safety and to determine the recommended Phase 2 dose (RP2D) of Nana-val in patients with EBV+ RM-NPC. In Phase 2, up to sixty patients with EBV+ RM-NPC will be randomized to receive Nana-val at the RP2D with or without pembrolizumab, to evaluate safety, overall response rate, and potential pharmacodynamic markers. Additionally, patients with other EBV+ solid tumors will be enrolled to receive Nana-val at the RP2D in a Phase 1b dose expansion cohort.


ę S&P Capital IQ 2021
All news about VIRACTA THERAPEUTICS, INC.
11/30INSIDER SELL : Viracta Therapeutics
MT
11/29Viracta Therapeutics Secures FDA Orphan Drug Designation for Lymphoma Combo Therapy
MT
11/29Viracta Therapeutics Gets FDA Orphan Drug Designation for Nana-val
DJ
11/29Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral ..
PR
11/11Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
AQ
11/10VIRACTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/10Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/10Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
PU
11/10SUNESIS : Q3 Earnings Snapshot
AQ
11/08Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and O..
AQ
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 153 M 153 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 24
Free-Float 85,3%
Chart VIRACTA THERAPEUTICS, INC.
Duration : Period :
Viracta Therapeutics, Inc. Technical Analysis Chart | VIRX | US92765F1084 | MarketScreener
Technical analysis trends VIRACTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 4,10 $
Average target price 33,50 $
Spread / Average Target 717%
EPS Revisions
Managers and Directors
Ivor Royston President, Chief Executive Officer & Director
Daniel R. Chevallard Secretary, Chief Operating & Financial Officer
Roger J. Pomerantz Chairman
Lisa Rojkjaer Chief Medical Officer
Ayman El-Guindy Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VIRACTA THERAPEUTICS, INC.-38.55%153
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298